small molecule

MACRILEN

MACIMORELIN ACETATE

Loss of exclusivityJanuary 2030FDA regulatory exclusivity expiry

CompanyAEterna Zentaris →See this company's full patent-cliff portfolio

Drug detail

Brand name	MACRILEN
Active ingredient	MACIMORELIN ACETATE
Strength	EQ 60MG BASE/POUCH
Dosage form	FOR SOLUTION
Route	ORAL
Modality	Small molecule
FDA approval	December 2017
Marketing status	DISCN

Listed patents

Patent	Expires	Type
8192719*PED	April 2028	—
8192719	October 2027	use U-2220

Regulatory exclusivity

Code	Expires
PED	January 2030
M-14	July 2029

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.